EIGR logo

Eiger BioPharmaceuticals (EIGR) Cash From Operations

Annual CFO

-$74.55 M
+$8.46 M+10.19%

December 31, 2023

Summary

Performance

1-Year Change

+10.19%

3-Year Change

-17.98%

5-Year Change

-74.7%

15-Year Change

-94.28%

EIGR Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

19.61%
EIGR annual cash flow from operations is higher than 19.61% of companies in Healthcare sector

High & Low

All-time High

-$1.58 M

3-Year Low

-$83.01 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
EIGR previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

N/A
EIGR next annual earnings announcement has not yet been scheduled

OtherEIGRcash flowmetrics:

Annual CFI

$74.23 M
EIGR annual cash flow from investing activities is $74.23 million

Annual CFF

$41.00 K
EIGR annual cash flow from financing activities is $41.00 thousand

Annual FCF

-$74.78 M
EIGR annual free cash flow is -$74.78 million

Annual CAPEX

$234.00 K
EIGR annual capital expenditures is $234.00 thousand

Quarterly CFO

-$13.95 M
+$600.00 K+4.12%

December 31, 2023

Summary

Performance

3-Month Change

+4.12%

1-Year Change

+37.28%

3-Year Change

+10.06%

5-Year Change

-11.61%

EIGR Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

26%
EIGR quarterly cash flow from operations is higher than 26% of companies in Healthcare sector

High & Low

All-time High

$27.60 M
EIGR quarterly cash flow from operations is currently -150.56% below its historical high of $27.60 million

3-Year Low

-$24.00 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2023
EIGR previous earnings announcement was published on Dec 31, 2023

Next Quarterly Earnings Report Date

N/A
EIGR next earnings announcement has not yet been scheduled

OtherEIGRcash flowmetrics:

Quarterly CFI

$12.00 M
EIGR quarterly cash flow from investing activities is $12.00 million

Quarterly CFF

$7000.00
EIGR quarterly cash flow from financing activities is $7000.00

Quarterly FCF

-$13.96 M
EIGR quarterly free cash flow is -$13.96 million

Quarterly CAPEX

$1000.00
EIGR quarterly capital expenditures is $1000.00

TTM CFO

-$74.55 M
+$8.29 M+10.01%

December 31, 2023

Summary

Performance

3-Month Change

+10.01%

1-Year Change

+10.19%

3-Year Change

-17.98%

5-Year Change

-17.19%

EIGR TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

20.87%
EIGR TTM cash flow from operations is higher than 20.87% of companies in Healthcare sector

High & Low

All-time High

$1.92 M
EIGR TTM cash flow from operations is currently -3986.76% below its historical high of $1.92 million

3-Year Low

-$88.85 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2023
EIGR previous earnings announcement was published on Dec 31, 2023

Next Quarterly Earnings Report Date

N/A
EIGR next earnings announcement has not yet been scheduled

OtherEIGRcash flowmetrics:

TTM CFI

$74.23 M
EIGR TTM cash flow from investing activities is $74.23 million

TTM CFF

$41.00 K
EIGR TTM cash flow from financing activities is $41.00 thousand

TTM FCF

-$74.78 M
EIGR TTM free cash flow is -$74.78 million

TTM CAPEX

$234.00 K
EIGR TTM capital expenditures is $234.00 thousand

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

EIGR Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+10.2%+37.3%+10.2%
3 y3 years-18.0%+10.1%-18.0%
5 y5 years-74.7%-11.6%-17.2%

EIGR Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-4.5%+10.2%at high+41.9%-4.5%+16.1%
5 y5-year-18.0%+10.2%at high+41.9%-23.5%+16.1%
alltimeall time-4612.3%+10.2%-150.6%+41.9%-3986.8%+16.1%

Eiger BioPharmaceuticals Cash From Operations History

DateAnnualQuarterlyTTM
Dec 2023
-$74.55 M(-10.2%)
-$13.95 M(-4.1%)
-$74.55 M(-10.0%)
Sep 2023
-
-$14.55 M(-34.0%)
-$82.84 M(-6.8%)
Jun 2023
-
-$22.04 M(-8.2%)
-$88.85 M(+0.3%)
Mar 2023
-
-$24.00 M(+7.9%)
-$88.56 M(+6.7%)
Dec 2022
-$83.01 M(+16.4%)
-$22.25 M(+8.2%)
-$83.01 M(+7.1%)
Sep 2022
-
-$20.56 M(-5.4%)
-$77.53 M(+1.7%)
Jun 2022
-
-$21.74 M(+17.8%)
-$76.23 M(+1.8%)
Mar 2022
-
-$18.46 M(+10.1%)
-$74.87 M(+4.9%)
Dec 2021
-$71.34 M(+12.9%)
-$16.77 M(-13.0%)
-$71.34 M(+1.8%)
Sep 2021
-
-$19.26 M(-5.5%)
-$70.09 M(+7.9%)
Jun 2021
-
-$20.38 M(+36.5%)
-$64.94 M(+7.6%)
Mar 2021
-
-$14.93 M(-3.8%)
-$60.38 M(-4.4%)
Dec 2020
-$63.19 M(-0.7%)
-$15.52 M(+10.0%)
-$63.19 M(+0.9%)
Sep 2020
-
-$14.11 M(-10.8%)
-$62.64 M(-0.8%)
Jun 2020
-
-$15.82 M(-10.8%)
-$63.12 M(+1.0%)
Mar 2020
-
-$17.74 M(+18.5%)
-$62.47 M(-1.8%)
Dec 2019
-$63.61 M(+49.1%)
-$14.97 M(+2.6%)
-$63.61 M(+4.0%)
Sep 2019
-
-$14.59 M(-3.8%)
-$61.15 M(+1.5%)
Jun 2019
-
-$15.17 M(-19.7%)
-$60.26 M(+13.7%)
Mar 2019
-
-$18.88 M(+51.0%)
-$52.98 M(+24.2%)
Dec 2018
-$42.67 M
-$12.50 M(-8.8%)
-$42.67 M(+5.2%)
Sep 2018
-
-$13.71 M(+73.7%)
-$40.56 M(+16.2%)
Jun 2018
-
-$7.89 M(-8.0%)
-$34.91 M(-2.9%)
DateAnnualQuarterlyTTM
Mar 2018
-
-$8.57 M(-17.5%)
-$35.94 M(-6.3%)
Dec 2017
-$38.37 M(+1.1%)
-$10.39 M(+29.0%)
-$38.37 M(-1.9%)
Sep 2017
-
-$8.06 M(-9.6%)
-$39.12 M(+2.0%)
Jun 2017
-
-$8.92 M(-19.0%)
-$38.36 M(-15.2%)
Mar 2017
-
-$11.01 M(-1.2%)
-$45.26 M(+19.2%)
Dec 2016
-$37.97 M(+315.7%)
-$11.14 M(+52.6%)
-$37.97 M(-5050.5%)
Sep 2016
-
-$7.30 M(-53.8%)
$767.00 K(-158.6%)
Jun 2016
-
-$15.82 M(+326.0%)
-$1.31 M(-168.2%)
Mar 2016
-
-$3.71 M(-113.5%)
$1.92 M(-121.0%)
Dec 2015
-$9.13 M(-68.8%)
$27.60 M(-394.3%)
-$9.13 M(-80.4%)
Sep 2015
-
-$9.38 M(-25.5%)
-$46.62 M(+7.0%)
Jun 2015
-
-$12.59 M(-14.7%)
-$43.57 M(+16.2%)
Mar 2015
-
-$14.77 M(+49.4%)
-$37.48 M(+28.1%)
Dec 2014
-$29.26 M(+80.7%)
-$9.88 M(+56.3%)
-$29.26 M(+20.9%)
Sep 2014
-
-$6.33 M(-2.7%)
-$24.19 M(+10.5%)
Jun 2014
-
-$6.50 M(-0.7%)
-$21.90 M(+13.5%)
Mar 2014
-
-$6.55 M(+35.9%)
-$19.29 M(+19.1%)
Dec 2013
-$16.20 M(+10.7%)
-$4.82 M(+19.6%)
-$16.20 M(+42.4%)
Sep 2013
-
-$4.03 M(+3.6%)
-$11.38 M(+54.8%)
Jun 2013
-
-$3.89 M(+12.5%)
-$7.35 M(+112.5%)
Mar 2013
-
-$3.46 M
-$3.46 M
Dec 2012
-$14.64 M(+825.2%)
-
-
Dec 2011
-$1.58 M(-71.8%)
-
-
Jun 2011
-$5.61 M
-
-

FAQ

  • What is Eiger BioPharmaceuticals annual cash flow from operations?
  • What is the all time high annual CFO for Eiger BioPharmaceuticals?
  • What is Eiger BioPharmaceuticals annual CFO year-on-year change?
  • What is Eiger BioPharmaceuticals quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Eiger BioPharmaceuticals?
  • What is Eiger BioPharmaceuticals quarterly CFO year-on-year change?
  • What is Eiger BioPharmaceuticals TTM cash flow from operations?
  • What is the all time high TTM CFO for Eiger BioPharmaceuticals?
  • What is Eiger BioPharmaceuticals TTM CFO year-on-year change?

What is Eiger BioPharmaceuticals annual cash flow from operations?

The current annual CFO of EIGR is -$74.55 M

What is the all time high annual CFO for Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals all-time high annual cash flow from operations is -$1.58 M

What is Eiger BioPharmaceuticals annual CFO year-on-year change?

Over the past year, EIGR annual cash flow from operations has changed by +$8.46 M (+10.19%)

What is Eiger BioPharmaceuticals quarterly cash flow from operations?

The current quarterly CFO of EIGR is -$13.95 M

What is the all time high quarterly CFO for Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals all-time high quarterly cash flow from operations is $27.60 M

What is Eiger BioPharmaceuticals quarterly CFO year-on-year change?

Over the past year, EIGR quarterly cash flow from operations has changed by +$8.29 M (+37.28%)

What is Eiger BioPharmaceuticals TTM cash flow from operations?

The current TTM CFO of EIGR is -$74.55 M

What is the all time high TTM CFO for Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals all-time high TTM cash flow from operations is $1.92 M

What is Eiger BioPharmaceuticals TTM CFO year-on-year change?

Over the past year, EIGR TTM cash flow from operations has changed by +$8.46 M (+10.19%)